CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03190174
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:50.831653+00:00
Published At: 2025-02-17T00:00:00+00:00
Record Updated At: 2025-02-17
Results Posted At: 2025-02-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-02-17"
protocolSection.identificationModule.nctId: "NCT03190174"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-02-17"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.